Arcturus Therapeutics Holdings Inc
ARCT
NASDAQ
Biotechnology
$8.23
USD
+0.37 (+4.71%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $222.41M
Volume 930.3K
Revenue
$29.37M
TTM
-76.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-93.28M
TTM
-55.0%
YoY
Operating Cash Flow
$-72.73M
TTM
-12.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 28.3 | 17.2 | 7.2 | 2.1 | 3.0 |
YoY Growth | -43.2% | -58.8% | -68.4% | -93.0% | -89.5% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 28.3 | 17.2 | 7.2 | 2.1 | 3.0 |
Selling, General & Administrative | 10.3 | 10.4 | 14.0 | 9.5 | 11.0 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 39.9 | 33.7 | 38.5 | 31.0 | 28.5 |
Operating Income | -11.6 | -16.5 | -31.3 | -28.9 | -25.5 |
EBITDA | -10.8 | -15.7 | -30.6 | -28.3 | -24.9 |
Other Income / Expense | -0.1 | 3.1 | 2.2 | 0.0 | -0.1 |
Total Other Income / Expense | 2.4 | 3.1 | 2.2 | 2.0 | 1.8 |
Income Before Income Taxes | -9.2 | -13.4 | -29.1 | -27.0 | -23.8 |
Income Taxes | 0.0 | 0.0 | -0.0 | 0.0 | 0.0 |
Net Income | -9.2 | -13.4 | -29.1 | -27.0 | -23.8 |
Consolidated Net Income / Loss | -9.2 | -13.4 | -29.1 | -27.0 | -23.8 |
Net Income Attributable to Common Shareholders | -9.2 | -13.4 | -29.1 | -27.0 | -23.8 |
Basic EPS | -$0.34 | -$0.49 | -$1.03 | -$0.95 | -$0.84 |
Diluted EPS | -$0.34 | -$0.49 | -$1.03 | -$0.95 | -$0.84 |
Basic Shares Outstanding | 27.1M | 27.2M | 28.1M | 28.4M | 28.4M |
Diluted Shares Outstanding | 27.1M | 27.2M | 28.1M | 28.4M | 28.4M |